DYNLL1通过ILF2/CDK4轴加速细胞循环,促进肝细胞癌的发展和palbociclib敏感度
Yuechen Liu1,2, Zhenkang Li1,2, Jinchao Zhang1,2
1Department of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, China.
British journal of cancer
|June 1, 2024
概括
氨酸轻链1 (DYNLL1) 通过激活ILF2/CDK4通路来驱动肝细胞癌 (HCC). 用palbociclib准CDK4/6,特别是与sorafenib结合使用,对治疗DYNLL1-过度表达的HCC有很大的希望.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 细胞周期失调是肝癌发生的一个关键驱动因素.
- 鉴定肝细胞癌 (HCC) 的有效治疗点仍然具有挑战性.
- 迪内因光链1 (DYNLL1) 涉及细胞循环进展和瘤发生.
研究的目的:
- 研究DYNLL1在调节HCC.细胞周期进展中的作用.
- 阐明DYNLL1在HCC中的功能背后的分子机制.
- 评估DYNLL1作为HCC中的预测生物标志物和治疗标.
主要方法:
- 对DYNLL1表达和预后价值的临床HCC标本的分析.
- 在各种HCC模型中的体外和体外功能增益/丧失实验.
- 质谱测量,RNA测序和共免疫沉以确定DYNLL1/ILF2/CDK4信号轴.
- 在HCC细胞和模型中对palbociclib和sorafenib的敏感性评估.
主要成果:
- 在HCC组织中,DYNLL1表达升高,与预后不佳相关.
- DYNLL1通过体外和体外模型促进肝癌发生.
- DYNLL1与ILF2相互作用,增强其表达,随后稳定CDK4mRNA,激活G1/S细胞周期基因.
- 作为CDK4/6抑制剂的Palbociclib在DYNLL1-过度表达的HCC.中显示出治疗潜力.
结论:
- DYNLL1通过协调细胞周期进展,在促进HCC发育方面发挥着至关重要的作用.
- DYNLL1/ILF2/CDK4轴代表了HCC病变发生的新途径.
- 与CDK4/6抑制剂 (palbociclib) 和索拉芬尼布的联合治疗为DYNLL1-高HCC患者提供了一个有前途的策略.
相关概念视频
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
DNA Damage can Stall the Cell Cycle
9.1K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
Positive Regulator Molecules
5.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.4K


